AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder - Slideshow

AtaiBeckley Inc. reported positive topline results from its Phase IIa study of EMP-01, an experimental treatment for social anxiety disorder, in February 2026. The exploratory trial demonstrated statistically significant improvements in primary and secondary endpoints, including reduced anxiety symptoms and enhanced social functioning. EMP-01, a novel psychedelic-derived compound, was well-tolerated with no serious adverse events reported, supporting its safety profile for further development. The company plans to advance EMP-01 into Phase IIb trials later this year, targeting a larger patient population to validate efficacy and optimize dosing. Investors reacted positively to the news, with ATAI’s stock rising on the announcement, reflecting confidence in the drug’s potential as a breakthrough therapy.